Insilico drug cuts biological age by up to 6 years in IPF trial

Insilico Medicine's announcement is a significant step for AI-driven drug discovery, suggesting that a molecule identified and designed by generative AI may have effects beyond its intended target. The company, which went public on the Hong Kong Stock Exchange in December 2025, has over 40 development programs in fibrosis, cancer, immunology, and metabolic diseases. This study leverages data from a Phase 2a trial of rentosertib in IPF, a progressive disease that hardens lung tissue, making it harder to take in oxygen.

The fact that six different aging clocks, built with different methods and goals, all showed a decline in biological age is notable because it implies the effect is not an artifact of a single model. However, the authors acknowledge that the small sample size and short duration limit the conclusions. The aging clock changes did not align with the group that showed the most lung function improvement, which could indicate that the effect on aging is separate from the drug's anti-fibrotic action, but this remains speculative.

The stakes are high: if further studies confirm that rentosertib genuinely slows biological aging, it could open the door to treating aging itself as a condition, not just age-related diseases. The outcome hinges on whether these findings are replicated in larger, longer trials, particularly the ongoing Phase 3 study. For now, the drug's potential as an anti-aging therapy remains unproven but intriguing, and the results highlight the growing promise of AI-designed molecules in medicine.